Targeted α-Particle Radiotherapy for Cancer

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Viewpoint is teaming with world-class companies and academic centers to bring its novel product line of therapeutics and complementary diagnostic imaging agents to personalized patient care for metastatic melanoma and neuroendocrine tumors.

Viewpoint Molecular TargetingTM Awarded $5 Million in Phase II SBIR Grants from the National Institutes of Health - National Cancer Institute

January 19, 2021 | Coralville, IA. Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision
α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has been awarded a total of $5 million in Phase II grants from the National Cancer Institute under the SBIR program and National Institutes of Health (NIH)...
READ MORE

Viewpoint Molecular TargetingTM Announces Closing of its Series A Financing with Proceeds of $13 Million

January 8, 2021 | Coralville, IA. Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, announced today it has closed the third and final tranche of its Series A financing for a total of approximately $13 million... READ MORE

Viewpoint Molecular Targeting™ Closes $8 Million in First Tranche of Series A Financing

December 15, 2020 | Coralville, IA. Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision α- particle oncology therapeutics and complementary diagnostic imaging agents, announced today it has closed the first tranche of approximately $8 million of its Series A financing. READ MORE

Get in Touch

Join Our Mailing List

Enter your email address below for occasional updates from Viewpoint Molecular Targeting

©2021, Viewpoint Molecular Targeting™.  All Rights Reserved.